Tag: Refractory colorectal cancer

Home / Refractory colorectal cancer

Categories

Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer

The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone sp...
refractory-colorectal-cancer

Scan the code